MTOR and tuberous sclerosis: Use of systemic mTOR inhibitors that include oral rapamycin/sirolimus or everolimus was reported by 16.7% and 31.8% caregivers, respectively, and 37.8% and 29.6% patients with TSC, respectively (Fig. 3A).